Clinical Trial Update: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial of GSK3117391 in rheumatoid arthritis terminated; results posted in 2019 focusing on efficacy, safety, tolerability, pharmacokinetics and pharmaco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GSK3117391 (GSK3117391)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: TERMINATED | Results posted: 2019-03-26